Combinations of LSD1 Inhibitors for the treatment of Haematological Malignancies, manufactured article, method of treatment and use

摘要

1. Claim 1: a mixture (1) comprising a formula compound,Or one or more drugs selected from retinal steroids, nucleic acid steroids, polychlorinated biphenyl inhibitors, hydrochlorination inhibitors, dechlorinating agents, FLT3 inhibitors, BCL2 inhibitors, MDM2 inhibitors, c-kit inhibitors and bet inhibitors, An anthrax, arsenic trioxide, hydroxyl group, and a salt acceptable to a drug. Claim 2: the combination of claim 1, including a formula compound (1),Or a medically acceptable salt and one or more therapeutics selected from the triprene, such as abina, sapassitabina, clorabina, elatarabina, fludarabina, trimethyl phosphate, gemcitabina, 2-chloro-2-herbicide (also known as Corno 2-CdA),troxacitabina forodesina nelarabina pinometostat EPZ-004777 SGC-0946 Belinostat Panobinostat Vorinostat Ricolinostat Entinostat Mocetinostat Abexinostat Resminostat Givinostat Quisinostat decitabina azacitidina guadecitabina Quizartinib Sorafenib Sunitinib Lestaurtinib ABT-737 Navitoclax Venetoclax Obatoclax Nutlina-3A dasatinib imatinib JQ1 GSK1210151A MS 436 GSK525762 OTX-015 CPI-203 GSK1324726A